Janus Henderson Global Life Sciences A (JFNAX)
58.99
+0.80 (+1.37%)
USD |
May 20 2022
Returns Chart
Key Stats
Customize
Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
---|---|---|---|
0.97% | 4.266B | 1.29% | 32.00% |
1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
-359.03M | -7.39% | Upgrade | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector. |
General | |
Security Type | Mutual Fund |
Oldest Share Symbol | JNGLX |
Equity Style | Large Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | Janus Henderson |
Prospectus Benchmark Index | |
MSCI World/Health Care NR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Andrew Acker | 15.01 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
87
-359.03M
-3.360B
Category Low
9.492B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
UnitedHealth Group Inc | 5.87% | 485.73 | 1.50% |
AstraZeneca PLC
|
4.50% | -- | -- |
AbbVie Inc | 3.87% | 151.01 | -0.47% |
Roche Holding AG
|
2.89% | -- | -- |
Thermo Fisher Scientific Inc | 2.70% | 555.15 | 0.80% |
Abbott Laboratories | 2.53% | 113.24 | 0.71% |
Eli Lilly and Co | 2.52% | 298.85 | 4.39% |
Bristol-Myers Squibb Co | 2.41% | 76.19 | 0.30% |
Boston Scientific Corp | 2.38% | 39.22 | -0.68% |
Danaher Corp | 2.35% | 251.80 | 1.00% |
Basic Info
Investment Strategy | |
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector. |
General | |
Security Type | Mutual Fund |
Oldest Share Symbol | JNGLX |
Equity Style | Large Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | Janus Henderson |
Prospectus Benchmark Index | |
MSCI World/Health Care NR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Andrew Acker | 15.01 yrs |
Fundamentals
General | |
Distribution Yield | Upgrade |
Dividend Yield TTM (5-20-22) | 1.29% |
30-Day SEC Yield (8-31-17) | Upgrade |
7-Day SEC Yield (12-18-12) | Upgrade |
Number of Holdings | Upgrade |
Stock | |
Weighted Average PE Ratio | 25.40 |
Weighted Average Price to Sales Ratio | Upgrade |
Weighted Average Price to Book Ratio | Upgrade |
Weighted Median ROE | Upgrade |
Weighted Median ROA | Upgrade |
Forecasted Dividend Yield | Upgrade |
Forecasted PE Ratio | Upgrade |
Forecasted Price to Sales Ratio | Upgrade |
Forecasted Price to Book Ratio | Upgrade |
As of March 31, 2022
Growth Estimates
Fund Details
Key Dates | |
Inception Date | 7/6/2009 |
Last Annual Report Date | 9/30/2021 |
Last Prospectus Date | 1/28/2022 |
Share Classes | |
JAGLX | Other |
JFNCX | C |
JFNIX | Inst |
JFNNX | N |
JFNSX | S |
JNGLX | D |
Attributes | |
Enhanced Index Fund | No |
Index Fund | No |
Inverse Fund | No |
Leveraged Fund | No |
Fund of Funds | No |
Currency Hedged Fund | No |
Synthetic Replication Fund | No |
Has Dividend Investment Plan | No |
Socially Responsible Fund | No |